Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-03 04:48 | 2025-07-01 | CALC | CalciMedica, Inc. | Stauderman Kenneth A. | Officer | BUY | $1.85 | 1,000 | $1,850 | 1,000 |
| 2025-07-03 00:28 | 2025-07-01 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Officer | SELL | $14.65 | 815 | $11,940 | 88,787 |
| 2025-07-02 23:33 | 2025-06-30 | FGEN | KYNTRA BIO, INC. | Schoeneck James A | Director | BUY | $5.07 | 23,567 | $119,485 | 39,666 |
| 2025-07-02 18:00 | 2025-06-30 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $5.78 | 6,500 | $37,570 | 0 |
| 2025-07-02 23:06 | 2025-07-01 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $98.33 | 6,830 | $671,612 | 233,924 |
| 2025-07-02 22:51 | 2025-07-01 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $33.55 | 5,000 | $167,750 | 398,108 |
| 2025-07-03 00:22 | 2025-07-01 | RMTI | ROCKWELL MEDICAL, INC. | Chole Timothy | Officer | SELL | $0.82 | 2,868 | $2,352 | 128,167 |
| 2025-07-03 00:20 | 2025-07-01 | RMTI | ROCKWELL MEDICAL, INC. | Neri Jesse | Officer | SELL | $0.82 | 886 | $727 | 126,614 |
| 2025-07-03 00:17 | 2025-07-01 | RMTI | ROCKWELL MEDICAL, INC. | Strobeck Mark | Director, Officer | SELL | $0.82 | 6,926 | $5,679 | 337,752 |
| 2025-07-02 23:15 | 2025-06-30 | PMN | ProMIS Neurosciences Inc. | GORDON MICHAEL S | 10% owner | SELL | $0.00 | 93,223 | $0 | 0 |
| 2025-07-01 23:30 | 2025-06-27 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $80.02 | 20,000 | $1,600,400 | 61,734 |
| 2025-07-01 23:22 | 2025-06-30 | ALXO | Alx Oncology Holdings Inc. | Pinto Shelly | Officer | SELL | $0.43 | 1,532 | $659 | 88,820 |
| 2025-07-01 23:37 | 2025-06-30 | CLYM | Climb Bio, Inc. | Brennan Aoife | Director, Officer | OPT+S | $1.22 | 20,618 | $25,154 | 48,132 |
| 2025-07-01 23:30 | 2025-06-30 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $35.52 | 6,918 | $245,727 | 526,034 |
| 2025-07-02 02:55 | 2025-06-27 | JUNS | JUPITER NEUROSCIENCES, INC. | Silva Alison D. | Director, Officer | BUY | $1.03 | 1,800 | $1,855 | 112,027 |
| 2025-07-02 02:55 | 2025-06-27 | JUNS | JUPITER NEUROSCIENCES, INC. | ROSEN CHRISTER | Director, Officer, 10% owner | BUY | $1.02 | 7,816 | $7,986 | 11,075,292 |
| 2025-07-01 23:42 | 2025-06-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $20.91 | 3,250 | $67,956 | 23,000 |
| 2025-07-02 03:33 | 2025-06-27 | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Director, 10% owner | SELL | $6.93 | 125,000 | $866,638 | 1,100,248 |
| 2025-07-01 23:49 | 2025-06-27 | QURE | uniQure N.V. | Abi-Saab Walid | Officer | SELL | $13.92 | 1,466 | $20,407 | 150,437 |
| 2025-07-01 23:55 | 2025-06-30 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $2.46 | 4,115 | $10,123 | 29,715 |
| 2025-07-02 00:01 | 2025-06-30 | AKBA | Akebia Therapeutics Inc. | Ostrowski Erik | Officer | SELL | $3.67 | 41,314 | $151,622 | 503,586 |
| 2025-07-02 04:17 | 2025-06-27 | CRVS | Corvus Pharmaceuticals, Inc. | Thompson Peter A. | Director, 10% owner | SELL | $4.16 | 1,176,332 | $4,891,894 | 7,165,006 |
| 2025-07-02 03:32 | 2025-06-27 | TRDA | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. | 10% owner | SELL | $6.93 | 125,000 | $866,638 | 1,100,248 |
| 2025-07-02 02:48 | 2025-06-27 | BBIO | BridgeBio Pharma, Inc. | VIKING GLOBAL INVESTORS LP | 10% owner | SELL | $44.00 | 3,500,000 | $154,000,000 | 18,555,375 |
| 2025-07-02 00:03 | 2025-06-27 | SION | Sionna Therapeutics, Inc. | TPG GP A, LLC | 10% owner | BUY | $15.84 | 60,000 | $950,400 | 6,744,962 |
| 2025-07-02 04:23 | 2025-06-27 | CRVS | Corvus Pharmaceuticals, Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | SELL | $4.16 | 1,176,332 | $4,891,894 | 7,165,006 |
| 2025-07-01 23:42 | 2025-06-27 | SPRY | ARS Pharmaceuticals, Inc. | Flynn James E | 10% owner | SELL | $18.46 | 740,149 | $13,663,151 | 4,887,254 |
| 2025-07-01 00:51 | 2025-06-26 | BBIO | BridgeBio Pharma, Inc. | Valantine Hannah | Director | SELL | $44.05 | 4,707 | $207,327 | 398 |
| 2025-07-01 00:49 | 2021-12-29 | BBIO | BridgeBio Pharma, Inc. | Valantine Hannah | Director | BUY | $14.24 | 1,752 | $24,948 | 3,294 |
| 2025-07-01 00:46 | 2021-12-28 | BBIO | BridgeBio Pharma, Inc. | Valantine Hannah | Director | BUY | $12.84 | 2,338 | $30,028 | 2,687 |
| 2025-06-30 20:03 | 2025-06-27 | ACTU | Actuate Therapeutics Inc. | Bios Equity COF, LP | Director, 10% owner | BUY | $7.00 | 71,428 | $499,996 | 196,428 |
| 2025-06-30 20:02 | 2025-06-27 | ACTU | Actuate Therapeutics Inc. | Kreis Leslie W. | Director, 10% owner | BUY | $7.00 | 71,428 | $499,996 | 196,428 |
| 2025-06-30 20:01 | 2025-06-27 | ACTU | Actuate Therapeutics Inc. | Fletcher Aaron G.L. | Director, 10% owner | BUY | $7.00 | 71,428 | $499,996 | 196,428 |
| 2025-07-01 00:38 | 2025-06-27 | TERN | Terns Pharmaceuticals, Inc. | Gengos Andrew | Officer | BUY | $3.93 | 10,000 | $39,283 | 25,000 |
| 2025-07-01 00:02 | 2025-06-26 | ZVRA | ZEVRA THERAPEUTICS, INC. | Thompson Rahsaan | Officer | SELL | $9.21 | 24,000 | $221,004 | 42,666 |
| 2025-06-30 16:09 | 2025-06-27 | IMRX | Immuneering Corp | Schall Thomas J. | Director | BUY | $3.66 | 9,500 | $34,788 | 52,885 |
| 2025-06-28 00:07 | 2025-06-26 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $78.71 | 4,000 | $314,826 | 48,034 |
| 2025-06-28 00:05 | 2025-06-25 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Officer | OPT+S | $79.88 | 10,800 | $862,704 | 63,101 |
| 2025-06-27 23:15 | 2025-06-26 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer | OPT+S | $36.13 | 5,877 | $212,348 | 39,098 |
| 2025-06-27 23:15 | 2025-06-26 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $36.13 | 23,669 | $855,208 | 514,982 |
| 2025-06-27 23:15 | 2025-06-26 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | OPT+S | $36.13 | 2,675 | $96,653 | 21,004 |
| 2025-06-27 23:27 | 2025-06-27 | NATR | NATURES SUNSHINE PRODUCTS INC | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% owner | SELL | $11.46 | 2,854,607 | $32,713,796 | 0 |
| 2025-06-28 02:35 | 2025-06-26 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $1.44 | 4,500 | $6,483 | 32,823 |
| 2025-06-27 23:39 | 2025-06-26 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $285.70 | 11,000 | $3,142,719 | 36,781 |
| 2025-06-27 23:15 | 2025-06-25 | AIMD | Ainos Inc. | lee ting-chuan | Director | SELL | $0.51 | 2,894 | $1,476 | 1,428,538 |
| 2025-06-27 23:15 | 2025-06-25 | AIMD | Ainos Inc. | TSAI CHUN-JUNG | Director | SELL | $0.50 | 17,000 | $8,539 | 1,384,997 |
| 2025-06-27 01:30 | 2025-06-26 | CALC | CalciMedica, Inc. | Bardin Stephen | Officer | BUY | $1.50 | 2,000 | $3,005 | 3,000 |
| 2025-06-26 16:07 | 2025-06-25 | RZLT | Rezolute, Inc. | ROBERTS BRIAN KENNETH | Officer | BUY | $4.38 | 2,500 | $10,939 | 15,500 |
| 2025-06-27 01:04 | 2025-06-24 | SLNO | SOLENO THERAPEUTICS INC | Hirano Patricia C | Officer | OPT+S | $84.25 | 266 | $22,411 | 17,036 |
| 2025-06-27 03:00 | 2025-06-24 | KALA | KALA BIO, Inc. | Kharabi Darius | Officer | SELL | $4.01 | 4,511 | $18,089 | 62,566 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.